AUROPHARMA.NS Balance Sheet
Aurobindo Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹7,995.38 Cr. | ₹11,545.51 Cr. | ₹12,189.43 Cr. | ₹14,329.93 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹4,496.40 Cr. | ₹2,739.39 Cr. | ₹3,266.00 Cr. | ₹3,008.83 Cr. | CapitalWorkInProgress |
| Goodwill | ₹596.07 Cr. | ₹595.15 Cr. | ₹618.02 Cr. | ₹800.15 Cr. | Goodwill |
| Other Intangible Assets | ₹2,432.24 Cr. | ₹2,352.13 Cr. | ₹1,986.74 Cr. | ₹2,276.50 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹301.74 Cr. | ₹226.87 Cr. | ₹206.16 Cr. | ₹195.04 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹705.45 Cr. | ₹613.25 Cr. | ₹730.93 Cr. | ₹828.32 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹18,344.32 Cr. | ₹20,865.88 Cr. | ₹22,622.51 Cr. | ₹25,793.40 Cr. | NoncurrentAssets |
| Inventories | ₹8,511.23 Cr. | ₹9,808.23 Cr. | ₹10,543.72 Cr. | ₹12,052.94 Cr. | Inventories |
| Trade Receivables | ₹4,466.38 Cr. | ₹4,816.74 Cr. | ₹5,745.93 Cr. | ₹7,094.37 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹4,396.29 Cr. | ₹3,393.48 Cr. | ₹5,568.95 Cr. | ₹7,191.40 Cr. | CashAndCashEquivalents |
| Current Investments | ₹151.00 Cr. | ₹50.58 Cr. | ₹0.01 Cr. | ₹747.24 Cr. | CurrentInvestments |
| Other Current Assets | ₹1,954.46 Cr. | ₹2,536.43 Cr. | ₹2,357.02 Cr. | ₹2,803.41 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹21,545.67 Cr. | ₹23,771.92 Cr. | ₹27,162.46 Cr. | ₹32,708.75 Cr. | CurrentAssets |
| Total Assets | ₹39,889.99 Cr. | ₹45,071.51 Cr. | ₹49,784.97 Cr. | ₹58,502.15 Cr. | Assets |
| Equity Share Capital | ₹58.59 Cr. | ₹58.59 Cr. | ₹58.08 Cr. | ₹58.08 Cr. | EquityShareCapital |
| Other Equity | ₹26,781.26 Cr. | ₹29,784.21 Cr. | ₹32,595.24 Cr. | ₹37,832.89 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹26,839.85 Cr. | ₹29,842.80 Cr. | ₹32,653.32 Cr. | ₹37,890.97 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹12.00 Cr. | ₹8.00 Cr. | ₹-6.39 Cr. | ₹-8.16 Cr. | NonControllingInterest |
| Total Equity | ₹26,851.85 Cr. | ₹29,850.80 Cr. | ₹32,646.93 Cr. | ₹37,882.81 Cr. | Equity |
| Long-term Borrowings | ₹618.96 Cr. | ₹2,134.90 Cr. | ₹1,561.65 Cr. | ₹802.75 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹1,544.36 Cr. | ₹3,021.58 Cr. | ₹2,455.70 Cr. | ₹2,580.33 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹4,242.56 Cr. | ₹4,180.32 Cr. | ₹6,380.03 Cr. | ₹6,873.45 Cr. | BorrowingsCurrent |
| Trade Payables | ₹3,871.31 Cr. | ₹4,454.16 Cr. | ₹4,188.85 Cr. | ₹5,567.27 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹1,143.25 Cr. | ₹877.38 Cr. | ₹546.83 Cr. | ₹626.30 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹11,493.78 Cr. | ₹12,199.13 Cr. | ₹14,682.34 Cr. | ₹18,039.01 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹39,889.99 Cr. | ₹45,071.51 Cr. | ₹49,784.97 Cr. | ₹58,502.15 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from AUROPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).